Role of Zidovudine and Candesartan in the Novel SARS-CoV-2 Treatment Trials
Theoretical Study
DOI:
https://doi.org/10.21467/preprints.30Abstract
The coronavirus disease 19 (COVID-19) is a highly communicable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which aroused in Wuhan, China and stretch around the humankind. Genomic analysis exposed that SARS-CoV-2 is phylogenetically associated to severe acute respiratory syndrome-like (SARS-like) bat viruses, hence bats could be the possible primary reservoir. The intermediate obtains of beginning and relocation to humans is not known, however, the rapid human to human transfer has been confirmed commonly. There is no approved antiviral medicine or vaccine ready to be used against COVID-19. However, there are a few broad-spectrum antiviral drugs have been estimated against COVID-19 in the current clinical trials, resulted in clinical recovery. In the current review, we summarize the possibility to use Zidovudine as antiviral drug and Candesartan as Angiotensin II Receptor Blocker (ARB) on the basis that Zidovudine works as RNA reverse transcriptase inhibitor (RTI), in addition to Candesartan which act as ARB, the receptors that bind to the spike protein (S-protein) present in the surface of coronavirus.
Keywords:
Coronavirus, SARS-CoV-2, COVID-19, Reverse Transcriptase Inhibitors (RTI), Candesartan, Zidovudine, Angiotensin II Receptor Blocker (ARB)Downloads
References
F. Wu, S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, et al.A new coronavirus associated with human respiratory disease in China; Nature., 1–5 (2020).
P. Zhou, X. Yang, X. Wang, B. Hu, L. Zhang, W. Zhang, et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin; Nature [Internet]., Feb (2020), p. 3.
X. Xu, P. Chen, J. Wang, J. Feng, H. Zhou, X. Li, et al.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission; Science China Life Sciences., 63 (3) (2020), pp. 457-460.
Y. Wan, J. Shang, R. Graham, R.S. Baric, F. LiReceptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS Journal of virology (2020).
The American Society of Health-System Pharmacists. Archived from the original on December 21, 2016. Retrieved November 28, 2016.
Mitsuya H, Weinhold K, Furman P, St Clair M, Li, Lars, Lehrman S, Gallo R, Bolognesi D, Barry D, Broder S (1985). "3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro". Proc Natl Acad Sci USA. 82 (20): 7096–100.
Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D, Gelmann E, Lehrman S, Blum R, Barry D (1986). "Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex". Lancet. 1 (8481): 575–80.
Mitsuya H, Yarchoan R, Broder S (1990). "Molecular targets for AIDS therapy". Science (Submitted manuscript). 249 (4976): 1533–44.
Quan, Y; Rong, L; Liang, C; Wainberg, MA (1999). "Reverse Transcriptase Inhibitors Can Selectively Block the Synthesis of Differently Sized Viral DNA Transcripts in Cells Acutely Infected with Human Immunodeficiency Virus Type 1". Journal of Virology. 73 (8): 6700–6707.
Downloads
Posted
Section
Categories
License
Copyright (c) 2020 Mohamed A. Mostafa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Any non-commercial use, distribution, adaptation, and reproduction in any medium is permitted as long as the original work is properly cited. However, caution and responsibility are required when reusing as the articles on the preprint server are not peer-reviewed. Readers are advised to check for the availability of any updated or peer-reviewed version.
